MIT nanolayered coating improves adherence to bone; India enables cheaper cardiac stent prices;

@FierceMedDev: Arch, a wound care device startup, raises $7.3M. Item | Follow @FierceMedDev

 @MarkHFierce: So, which med tech companies are facing FDA warning letters this week? Roundup | Follow @MarkHFierce

@DamianFierce: Edwards prevailed in the latest round of its heart valve patent dispute with Medtronic. Report | Follow @DamianFierce

> Massachusetts Institute of Technology researchers have come with a new nanolayered coating designed to help implants better adhere to bone. Story

> Retina Implant AG obtained a CE mark for the Alpha IMS, a subretinal implant designed to treat the degenerative eye condition known as retinitis pigmentosa. Item

> For new diagnostic tests to be successful, they must address a clear unmet need, produce actionable results and also be viable as part of a physician's clinical decision-making process, experts say. Story

> Who are some of North Carolina's top VC firms? Item (sub. req)

> India has taken further steps to slash the price of cardiac stent implants. Story

> Zinc may be an ideal material for bioabsorbable stents, Michigan Technology University researchers have found. Story

Biotech News

@FierceBiotech: ICYMI yesterday: The 2013 biotech IPO scene turns red hot. Special report | Follow @FierceBiotech

 @JohnCFierce: Afatinib OK'd for lung cancer. To be sold as Gilotrif? Sounds like a character in Lord of the Rings. FDA release | Follow @JohnCFierce

@RyanMFierce: Mitsubishi to snap up vaccine developer Medicago in $357M deal. News | Follow @RyanMFierce

 @EmilyMFierce: In case you missed it yesterday: Senate committee approves funding increase for NIH in FY 2014. Article | Follow @EmilyMFierce

> New rules push drug trials out of India. Item

> Agios Pharma sets terms for closely watched biotech IPO. Article

> In hot biotech market, personalized drugs rise to the top. Story

> Aveo hit with SEC subpoena on tivozanib after FDA slap-down. Report

Pharma News

@FiercePharma: CEO Joe Jimenez figures Novartis can grow "slightly faster than the market" in China: Report | Follow @FiercePharma

 @EricPFierce: BMS, Pfizer say FDA to review Eliquis for new use. Yesterday's story | Follow @EricPFierce

 @CarlyHFierce: Vivus urges shareholders to vote as meeting nears; First Manhattan trying to instate 9 board members. ICYMI yesterday | Follow @CarlyHFierce

> FDA approval for Boehringer means fast competition to Roche's targeted Tarceva. Article

> Sanofi starts producing dengue vax in effort to keep lead in lucrative space. Report

> Telegraph: Sources say 30 GSK employees under house arrest. Story

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.